ABSTRACT OF THE WEEK

Veterinary ophthalmology
Volume 24 Suppl 1 | Issue 0 (March 2021)

Pharmacologic ciliary body ablation for chronic glaucoma in dogs: A retrospective review of 108 eyes from 2013 to 2018.

Vet Ophthalmol. March 2021;24 Suppl 1(0):125-130.

Martha E Julien¹, Simone A Schechtmann², Tammy M Michau³, Anja Welihozkiy⁴, Terri L Baldwin⁵, Jessica M Stine⁶

¹ BluePearl Veterinary Partners, Tampa, FL, USA.; ² BluePearl Veterinary Partners, Tampa, FL, USA.; ³ BluePearl Veterinary Partners, Tampa, FL, USA.; ⁴ BluePearl Veterinary Partners, Sarasota, FL, USA.; ⁵ BluePearl Veterinary Partners, Clearwater, FL, USA.; ⁶ BluePearl Veterinary Partners, Clearwater, FL, USA.

Abstract

OBJECTIVE:To evaluate the long-term outcome and efficacy of intravitreal injection of gentamicin and dexamethasone sodium phosphate (IVGD) or triamcinolone in end-stage glaucoma patients and determine pre-procedure prognostic indicators of success and post-operative complications.

PROCEDURE:Medical records were reviewed for 108 dogs (108 eyes) treated with intravitreal gentamicin with or without dexamethasone sodium phosphate or triamcinolone for glaucoma between 2013 and 2018 with 3 months of minimum follow-up. Signalment and clinical findings, including type of glaucoma, pre-procedure intraocular pressure (IOP), chronicity, procedure protocol, and outcome were recorded. Success was defined as an intraocular pressure of ≤25 mm Hg at the time of last re-examination or no ocular hypotensive medications at 3 months or longer post-injection.

RESULTS:The overall success rate for pharmacologic ablation was 95%. The success rate for dogs receiving no ocular hypotensive medications was 86%. Seventy-six eyes (70.4%) had primary glaucoma, and 32 eyes (29.6%) had secondary glaucoma. Age at the time of injection had no effect on initial success but did in final success (P =-.03) for dogs requiring repeat injections. Cocker Spaniels required the most repeat 2nd and 3rd injections (3/12 dogs) and (2/4 dogs), respectively. No preoperative variable significantly affected the success rate. The most common complications were phthisis bulbi (59.2%), corneal edema (25.9%), and ulcerative keratitis (22.3%). Uncontrolled IOP resulted in enucleation in two dogs (1.8%).

CONCLUSIONS:Pharmacologic ablation has a high overall success rate in lowering IOP to ≤25 mm Hg short-term in blind, glaucomatous canine eyes. Type of glaucoma, pre-procedure IOP, chronicity, and protocol did not affect success.

Companion Notes

Retrospective report on pharmacologic ciliary body ablation for chronic glaucoma in 108 dogs

- intravitreal gentamicin and dexamethasone sodium phosphate or triamcinolone

Introduction on the treatment of chronic glaucoma

- primary glaucoma is typically genetic

(bilateral with predisposition for certain breeds)

- has 2 main forms based on gonioscopy of the drainage angle

- primary open angle glaucoma

- primary closed angle glaucoma

- secondary glaucoma is associated with ocular and systemic diseases

- painful and difficult to manage with medical and surgical intervention

- pharmacologic ablation of the ciliary body or ciliary body ablation (CBA)

- generally doesn’t require anesthesia

- owners may prefer it cosmetically compared to enucleation or evisceration

- procedure involves vitreocentesis

- followed by an injection of dexamethasone sodium phosphate

- in conjunction with a recommended dose of 15-30 mg gentamicin

- gentamicin is toxic to the ciliary body epithelium

- previously reported success rate in lowering IOP: 65%

- 86.4% reported more recently for ciliary body ablation with gentamicin

Study design

- study population: dogs seen at ophthalmology service of 4 referral hospitals

- inclusion criteria:

- end-stage glaucoma

- chronic glaucomatous, avisual eyes refractory to medical therapy

- diagnosis of chronic glaucoma was based on the following:

- IOP ≥ 25 mm Hg

- absent menace response and dazzle reflexes

- ocular changes, including the following:

- episcleral injection

- buphthalmos

- corneal edema

- secondary lens luxation or subluxation

- posterior segment changes noted included the following:

- optic nerve atrophy

- optic disk cupping

- retinal vascular attenuation

- intravitreal gentamicin

- with or without dexamethasone sodium phosphate or triamcinolone

- 3 month minimum followup

- exclusion criteria:

- previous glaucoma surgery

- previous diagnosis of intraocular neoplasia

- history and signalment

- mean age of the 108 dogs in study at time of the procedure:

- 9.5 ± 2.7 years with a range of 2-16 years

- breeds represented by 5 or more cases

- cocker spaniel, overrepresented with 24 cases

- shih tzu, 8

- Labrador retriever, 6

- Siberian husky, 5

- Bichon Frise, 5

- procedure: records between 2013 and 2018 retrospectively reviewed

- 1 eye from bilateral cases randomly selected for analysis

- success defined as intraocular pressure ≤ 25 mm Hg at last re-examination

- or no ocular hypotensive medications at 3 months or longer post-injection

- diagnosis of canine primary glaucoma based on the following:

- elevated intraocular pressure

- optic nerve changes

- lack of readily identifiable concurrent ocular or systemic diseases

(on routine ophthalmic examination)

- causes of secondary glaucoma included the following:

- hypermature cataracts

- lens luxation

- pigmentary uveitis

- cataract surgery

- retinal detachment

- chronic uveitis

- lipid uveitis

- trauma

- procedure (dogs had sedation or anesthesia for bilateral procedures)

- intended eye(s) aseptically prepared with 0.5% betadine solution

- topical proparacaine hydrochloride 0.5% applied

- followed by topical phenylephrine 2.5%

- for conjunctival and episcleral hemostasis

- vitreocentesis using 25 gauge, 1-inch hypodermic needle

- inserted 6-8 mm posterior to the limbus to reduce IOP

- 0.5-0.6 mL of vitreous aspirated

- followed by 30-50 mg of gentamicin (100 mg/mL)

(1 ophthalmologist based dose on dog’s weight and another used

a standard dose of 30 mg)

- combined with 1 of the following:

(for injection-related inflammation)

- 0.4 mg of dexamethasone sodium phosphate (4 mg/mL)

- 1-2 mg of triamcinolone (2 mg/mL)

- immediate post-injection IOP recorded

- if IOP remained ≥ 25 mm Hg, aqueocentesis performed

- using 27-30 gauge, 1-inch hypodermic needle

Results

- overall success rate: 95%

- success rate for dogs receiving no ocular hypotensive medications: 86%

- type of glaucoma in the 108 eyes

- 76 eyes (70.4%) had primary glaucoma

- 32 (29.6%) had secondary glaucoma

- cataract surgery, 14 eyes

- hypermature cataracts, 6

- pigmentary uveitis, 4

- retinal detachment, 3

- anterior lens luxation, 2

- single eyes with either anterior uveitis, trauma, or lipid uveitis, 0.9%

- effect of age at the time of injection

- no effect on initial success

- did effect final success for dogs requiring repeat injections

- all cases that needed repeat injections were 6 years or older

- 12 dogs required a 2^nd intravitreal injection

- at a mean of 208 ± 157.9 days after the first

- 3^rd injection, 4 dogs

- cocker spaniels required the most repeat injections

(3 of 12 required a 2^nd injection and 2 of 4 required a 3^rd injection)

- no preoperative variable found to significantly affect the success rate

- including type of steroid used and the dose of both steroid and gentamicin

- complications

- phthisis bulbi, 59.2%

- corneal edema, 25.9%

- ulcerative keratitis, 22.3%

- subconjunctival hemorrhage, 9.2%

- hyphema, 8.3%

- cataracts, 6.4%

- endophthalmitis, 3%

- enucleation due to uncontrolled IOP, 2 dogs

“Primary versus secondary glaucoma cases did not show a difference in the success rate. Moreover, neither lens luxation as a cause of secondary glaucoma nor chronicity of disease affected the success rate.”

Keywords

canine; ciliary body ablation; gentamicin; glaucoma; intravitreal injection; pharmacologic ablation;

Article Tools:

Medline

Email to me

Grants:

BluePearl Science

Archives Highlights:

Feline acute patient physiologic and laboratory evaluation scores and other prognostic factors in cats with first-time diabetic ketoacidosis.
Median BG was significantly higher in non-survivors (431 mg/dL) compared with survivors (343 mg/dL) and BG predicted mortality. For every 1 mg/dL increase in BG, the odds of death increased by 1.004.

Recovery of ambulation in small, nonbrachycephalic dogs after conservative management of acute thoracolumbar disk extrusion.
Forty-nine of fifty-one (96%) of deep pain-positive and 10/21 (48%) of deep pain-negative dogs recovered ambulation within the 12-week period. The median time to ambulation was 11 and 25 days for deep pain-positive and -negative dogs, respectively. Reduction in spinal cord compression varied among individuals from minimal to complete and apparently was unrelated to the recovery of ambulation.

Value of repeated health screening in 259 apparently healthy mature adult and senior cats followed for 2 years.
Within 2 years, 28% of mature adult and 54% of senior cats that were confirmed healthy at inclusion developed new diseases, most commonly IRIS = stage 2 CKD (cumulative incidence, 13.4%), hyperthyroidism (8.5%), chronic enteropathy, hepatopathy or pancreatitis (7.5%), or neoplasia (7%). The high prevalence and 2-year incidence of physical examination abnormalities and systemic diseases in apparently healthy older cats argue for regular health screening in cats at least 7 years of age.

Prevalence of Encephalitozoon hellem among companion and exhibition birds in Japan.
Although microsporidia can rarely cause severe systemic infections, including hepatitis, nephritis, and enteritis in young birds, most infected birds are subclinical and thought to recover spontaneously after a period of temporary spore shedding if they do not have immunosuppression. Microsporidia can cause self-limiting infection in immunocompetent humans and life-threatening chronic diarrhea in immunocompromised individuals.

Life tables of annual life expectancy and risk factors for mortality in cats in the UK.
Life expectancy at age 0 for UK companion cats overall was 11.74 years. Among the 12 breeds (including crossbred) analysed, Burmese and Birman had the longest life expectancy at year 0, showing 14.42 years and 14.39 years, respectively. Sphynx had the shortest life expectancy at year 0 among the analysed breeds at 6.68 years. Being entire, purebred, and with a non-ideal body weight were significantly linked to a decreased lifespan.